Screening method of anticancer agent focused on function of hp1 and evaluation system
AssigneeJapanese Foundation for Cancer Research
InventorsToru Hirota, Yusuke Abe
Life of this patent
Estimating the term…
Abstract
The inventors have found that the interaction between HP1 and INCENP can serve as an indicator for chromosome instability and established a method for evaluating chromosome instability of cancer cells. The evaluation system can be used for screening of anticancer agent with a new-concept of targeting chromosome instability of cancer cells. The inventors further prepared an antibody for specifically recognizing phosphorylation of serine at position 92 of HP1α, by which the action of Aurora B can be evaluated. The interaction between HP1 and INCENP can be readily evaluated by the antibody.
Claims16
A method for evaluating chromosome instability, comprising determining Aurora B activity based on phosphorylation of HP1α and/or HP1γ as an indicator.
A method for screening for an anticancer agent, comprising
- using a change of interaction or binding between HP1 and INCENP as an indicator.
An antibody for specifically recognizing phosphorylation of serine at position 92 of HP1α or serine at position 83 of HP1γ, or a functional fragment thereof.
A method for using an antibody for specifically recognizing phosphorylation of serine at position 92 of HP1α and/or serine at position 83 of HP1γ, comprising detecting phosphorylation of HP1α and/or HP1γ to determine Aurora B activity and/or chromosome instability.
Dependencies are inferred from the claim text.